Solabegron
From Self-sufficiency
Revision as of 16:50, 30 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s): gastrointestinal-drug-, genito-urinary-drug-stub)
| File:Solabegron-2d-skeletal.png | |
| Systematic (IUPAC) name | |
|---|---|
|
3'-[(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]biphenyl-3-carboxylic acid | |
| Identifiers | |
| CAS Number | 451470-34-1 |
| ATC code | none |
| PubChem | CID 6433123 |
| Synonyms | 3-(3-(2-[(2-(3-chlorophenyl)-2-hydroxyethyl)amino]ethylamino)phenyl)benzoic acid |
| Chemical data | |
| Formula | C23H23ClN2O3 |
| Molar mass | 410.892 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Solabegron (GW-427,353) is a drug which acts as a selective agonist for the β3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome.[1],[2],[3] It has been shown to produce visceral analgesia by releasing somatostatin from adipocytes. [4],[5]
Synthesis
K.H. Donaldson, B.G. Shearer, D.E. Uehling, U.S. Patent 6,251,925 (2001).
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 45px | This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. |
| 40px | This drug article relating to the genito-urinary system is a stub. You can help ssf by expanding it. |
- ↑ Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, Luce TD, Coatney RW, Rivera GC, Westfall TD, Hieble JP. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. Journal of Pharmacology and Experimental Therapeutics. 2007 Oct;323(1):202-9. PMID 17626794
- ↑ Grudell AB, Camilleri M, Jensen KL, Foxx-Orenstein AE, Burton DD, Ryks MD, Baxter KL, Cox DS, Dukes GE, Kelleher DL, Zinsmeister AR. Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2008 May;294(5):G1114-9. PMID 18372395
- ↑ Kelleher DL, Hicks KJ, Cox DS, et al. Randomized, double-blind, placebo (PLA)- controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2008;20 (Suppl 2):131.
- ↑ Cellek S, Thangiah R, Bassil AK, Campbell CA, Gray KM, Stretton JL, Lalude O, Vivekanandan S, Wheeldon A, Winchester WJ, Sanger GJ, Schemann M, Lee K. Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology. 2007 Jul;133(1):175-83.
- ↑ Schemann M, Hafsi N, Michel K, Kober OI, Wollmann J, Li Q, Zeller F, Langer R, Lee K, Cellek S. The beta3-adrenoceptor agonist GW427353 (solabegron) decreases excitability of human enteric neurons via release of somatostatin. Gastroenterology 2009 Sep 25. [Epub ahead of print]
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Beta-adrenergic agonists
- Organochlorides
- Alcohols
- Aromatic amines
- Benzoic acids
- Gastrointestinal system drug stubs
- Genito-urinary system drug stubs
